Cargando…

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis

Interleukin (IL)-6 has a variety of biological functions. For example, it stimulates the production of acute-phase reactants (C-reactive protein and serum amyloid A) and hepcidin which interferes with iron recycling and absorption, causing iron-deficient anemia, and augments expression of vascular e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mihara, Masahiko, Ohsugi, Yoshiyuki, Kishimoto, Tadamitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074778/ https://www.ncbi.nlm.nih.gov/pubmed/27790001 http://dx.doi.org/10.2147/OARRR.S17118

Ejemplares similares

Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF-α Antibody in Mice
por: Okada, Masaji, et al.
Publicado: (2011)

346 Clinical Effects of Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, on Patients with Autoimmune and Allergic Diseases
por: Tanaka, Toshio, et al.
Publicado: (2012)

Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
por: Yanagida, Mitsuaki, et al.
Publicado: (2013)

Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
por: Hoffman, Elinoar, et al.
Publicado: (2019)

The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
por: Hashizume, Misato, et al.
Publicado: (2011)

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
por: Koike, Ryuji, et al.
Publicado: (2009)

Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
por: Hashimoto, Motomu, et al.
Publicado: (2014)

The in vivo Anti‐tumor Effect of Human Recombinant Interleukin‐6
por: Kitahara, Misa, et al.
Publicado: (1990)

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
por: Shima, Yoshihito, et al.
Publicado: (2010)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
por: Patel, Aarat M, et al.
Publicado: (2010)

Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
por: Kumar, Abhishek, et al.
Publicado: (2022)

Exploring the Role of Interleukin-6 Receptor Inhibitor Tocilizumab in Patients with Active Rheumatoid Arthritis and Periodontal Disease
por: Ancuța, Codrina, et al.
Publicado: (2021)

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
por: Isaacs, John D, et al.
Publicado: (2013)

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
por: Nishimoto, Norihiro, et al.
Publicado: (2008)

The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicine
por: Ohsugi, Yoshiyuki
Publicado: (2019)

Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis
por: Tada, Asumi, et al.
Publicado: (2012)

Interleukin-6: discovery of a pleiotropic cytokine
por: Kishimoto, Tadamitsu
Publicado: (2006)

Mouse Anti‐human Interleukin‐6 Receptor Monoclonal Antibody Inhibits Proliferation of Fresh Human Myeloma Cells in vitro
por: Goto, Hideo, et al.
Publicado: (1994)

Development of type 1 diabetes in a patient treated with anti‐interleukin‐6 receptor antibody for rheumatoid arthritis
por: Kawasaki, Eiji, et al.
Publicado: (2021)

Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors
por: Kobayashi, Tetsuo, et al.
Publicado: (2015)

A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential
por: Liu, Xiaolei, et al.
Publicado: (2022)

Interleukin-6 receptor in the recent-onset rheumatoid arthritis
por: Montes-Cano, Marco Antonio, et al.
Publicado: (2011)

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
por: Dayer, Jean-Michel, et al.
Publicado: (2010)

Interleukin 6 and Rheumatoid Arthritis
por: Yoshida, Yuji, et al.
Publicado: (2014)

Interleukin-6 in Rheumatoid Arthritis
por: Pandolfi, Franco, et al.
Publicado: (2020)

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
por: Tanaka, Toshio, et al.
Publicado: (2012)

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
por: Kang, Sujin, et al.
Publicado: (2021)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
por: Higuchi, Tomoaki, et al.
Publicado: (2010)

Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti-Interleukin-6 Receptor Antibody
por: Lurati, Alfredomaria, et al.
Publicado: (2012)

Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis
por: De La Torre, Miguel, et al.
Publicado: (2011)

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
por: Yokota, S, et al.
Publicado: (2013)

Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis
por: Nguyen, Nam Trung, et al.
Publicado: (2015)

Improvements in Intractable Lumbar and Lower-Extremity Symptoms after Systemic Administration of Tocilizumab, an Anti-interleukin-6 Receptor Antibody
por: Sainoh, Takeshi, et al.
Publicado: (2022)

Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity
por: Miyahara, Daisuke, et al.
Publicado: (2021)

Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
por: Chatzidionysiou, Katerina, et al.
Publicado: (2021)

Historical overview of the interleukin-6 family cytokine
por: Kang, Sujin, et al.
Publicado: (2020)

Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema
por: Pham, Brandon Huy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_84bjjphnvk2gbsfh7dhlilfe50